Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BMS-986504 perioperative study in recurrent MTAP-deleted glioblastoma
ACTRN12625001238460Phase 2Not yet recruiting
- Sponsor
- Peter MacCallum Cancer Centre
- Start
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of MRTX1719 in glioblastoma (GBM), sponsored by Peter MacCallum Cancer Centre. Primary endpoints: Safety of peri-operative BMS-986504 and Feasibility of perioperative study. Planned start Dec 2025; status: not yet recruiting.
02
Drugs
MRTX1719
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on ACTRN12625001238460.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12625001238460.